Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Chimeric-anti-interleukin-6 monoclonal antibody

EU orphan designation number: EU/3/07/508   
Active ingredient: Chimeric-anti-interleukin-6 monoclonal antibody
Indication: Treatment of Castleman’s disease
Sponsor: Janssen-Cilag International NV
Turnhoutseweg 30, B-2340 Beerse, België
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Sylvant on 22/05/2014 with the number EU/1/14/928

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
04/12/2007 Centralised Orphan - Designation EMEA/OD/078/07 (2007)6048 of 30/11/2007
24/08/2011 Other procedure EMEA/OD/078/07
11/06/2013 Centralised Orphan - Transfer of orphan designation EMEA/OD/078/07/T/01 (2013)3673 of 07/06/2013